Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?
about
Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare needNational trends in statin use by coronary heart disease risk categoryUndertreatment and overtreatment with statins: the Oslo Health Study 2000-2001Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service FrameworkPrevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based studyGender differences in the clinical management of patients with angina pectoris: a cross-sectional survey in primary careHow equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West EnglandImportance of socioeconomic status as a predictor of cardiovascular outcome and costs of care in women with suspected myocardial ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-sponsored Women's IscNeighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: atherosclerosis risk in communities (ARIC) community surveillance.Statins and their interactions with other lipid-modifying medications: safety issues in the elderlyThe use of lipid-lowering drugs across ethnic groups in the secondary prevention of ischaemic heart disease: analysis of cross-sectional surveys in England.Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study.Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England.Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001.Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective cohort study.Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care.Achieving lipid goals in Europe: how large is the treatment gap?Statin use after acute myocardial infarction: a nationwide study in DenmarkSocioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study.Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort.Neighborhood socioeconomic characteristics and statin medication in patients with myocardial infarction: a Swedish nationwide follow-up studyEvaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough.Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients.Which doctors are influenced by a patient's age? A multi-method study of angina treatment in general practice, cardiology and gerontology.The use of cholesterol-lowering medications after coronary revascularization.Effects of an enhanced secondary prevention program for patients with heart disease: a prospective randomized trial.Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study.Cardiorespiratory risk factors as predictors of 40-year mortality in women and menPotential for statins in the chemoprevention and management of hepatocellular carcinoma.Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities?Inequity in cardiovascular care in the English National Health Service (NHS): a scoping review of the literature.The impact of social deprivation on coronary revascularisation treatment outcomes within the National Health Service in England and Wales.Inequalities in access to care for patients with ischaemic heart disease.Challenges in preventing cardiovascular complications in type 2 diabetes in primary care.Patients with acute coronary syndrome should start a statin while still in hospital.Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies.Treatment gap in the use of lipid-lowering drug therapy in diabetes: a population-based study.Prescribing in general practice for people with coronary heart disease; equity by age, sex, ethnic group and deprivation.Statin-prescribing trends for primary and secondary prevention of cardiovascular disease.
P2860
Q24804642-492C464E-B8B9-4FDC-BEBD-7668DF4248A8Q24810059-F69EFBAC-464A-46F0-A89E-2C7460D79740Q28168028-44778A07-21DC-41BC-A765-033EF127915AQ28191878-AFC0B298-A547-4B03-B709-BB43EE77C7FEQ28194404-EA3CA22D-AAA9-4F58-8852-154EA6B3F49CQ28220836-F999FFEF-A0E8-486B-8409-B9C027DE1441Q28221444-257AC718-56D5-4D1B-8C07-2171D2CDC347Q33639322-0CB170A2-2804-4D3C-9B06-7FBFABB030E1Q33724790-A41C3A5C-6383-4C84-928D-25FE5A4F3FE7Q33949348-F90922CC-BAC4-4B3B-86F3-25AF28C304FDQ34098895-94C77B9C-CB8F-4BBB-B28F-98F2E6B800E2Q34366183-50C4C0F9-6E19-4D97-8B1E-80B7DC1BF768Q35414428-86D03807-952F-417C-9D97-1004CBBF0ED6Q35580925-9FB578CF-5B0D-4C90-8FCF-B012238CD2CCQ35585129-9096DB3A-18E4-4652-9732-D9C42FBD6271Q35644891-682E9918-1B1E-440D-910D-9D2EC41DC2FAQ35772239-6E5850A2-EBA1-4A55-B136-3DF7927E794EQ35777411-82E9730B-17E6-48E4-9D69-31F79BEAB3E9Q35827170-72A7DDA7-4813-44B1-AB53-64ABDE0DE300Q35827218-4484E8C6-A0DD-4C75-96F4-5657337D849BQ35990657-983CE761-C1E2-42A6-BA03-C1C5819FF8A3Q36071010-A981E001-9AA5-4D1D-BA73-917E4A379E64Q36374194-4148F7A3-5977-49B6-BEB6-3ED4ED461290Q36761556-FEB706CB-A9E5-4E80-85A7-5077670EE96DQ36767327-5CD513AE-6356-48C0-898E-E08A52A0955AQ37113166-7595CBB6-B634-4007-A637-5B78DC833E73Q37119082-3342A914-5F80-4FEA-878F-B4ED8143BB8BQ37297492-8712BC09-CED2-43D1-8070-F44BC84F9ECDQ37353643-5E091BBF-AFF8-4A30-8F73-C203B1F99743Q38030991-99A2D128-736C-44C4-B1B5-70200919E76AQ38045284-F3679BCF-B6B1-4BFC-9648-901D1C2DE82FQ38409844-DBAEA157-0A93-435E-8A4F-74FA1CDCD55FQ41582076-679D5562-2F5E-4D05-A3D2-C579A823EDA8Q42590598-95F46173-AB90-419E-A8CA-FC73E4DEC036Q42653963-29E47948-A09F-4D15-AD7E-C6868DB4C9DBQ42700220-35B53883-4799-4D74-9E73-0047A9D58BF7Q44560037-7E3345F3-0440-4BE5-84CC-5F1331ED8654Q45072228-2FDB2AE3-4742-4EFB-A5D4-1C0EA3D41B17Q46017191-65AB7CCF-9A53-46EA-8EA6-F730C7F72D93Q47109312-595F338F-5E3B-4F5A-A457-F38D1EBCAB30
P2860
Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Use of statins in the secondar ...... sease: is treatment equitable?
@ast
Use of statins in the secondar ...... sease: is treatment equitable?
@en
type
label
Use of statins in the secondar ...... sease: is treatment equitable?
@ast
Use of statins in the secondar ...... sease: is treatment equitable?
@en
prefLabel
Use of statins in the secondar ...... sease: is treatment equitable?
@ast
Use of statins in the secondar ...... sease: is treatment equitable?
@en
P2860
P356
P1433
P1476
Use of statins in the secondar ...... sease: is treatment equitable?
@en
P2093
P2860
P356
10.1136/HEART.88.1.15
P407
P577
2002-07-01T00:00:00Z